Pharma mulls $100M reform-ad campaign

You've heard that drugmakers have funded a new Harry-and-Louise ad campaign for healthcare reform. You may have even seen some of the commercials. Well, get ready for lots more pharma-backed advertising--because the industry is considering ploughing $100 million or more into a campaign beginning as early as September, sources told Bloomberg.

The current plan is to run television commercials in August in states where drugmakers maintain operations, depicting pharma as a linchpin of local economies, PhRMA SVP Ken Johnson told the news service. Then in September, PhRMA may back a huge healthcare reform push, with ads aimed at supporting reform efforts the industry can believe in.

We already know what the industry doesn't believe in: government price negotiation, even for Medicare drugs. That's one reason why pharma was so quick to step up with promises of cost cuts. That $80 billion pledge was designed to forestall provisions drugmakers don't like, such as price negotiation and drug reimportation from lower-cost markets such as Canada. Now, of course, that agreement looks rather limited, because a) the House doesn't recognize it, because it was settled with Sen. Max Baucus; and b) some Democratic Senators are saying pharma price cuts shouldn't be off the table. No wonder drugmakers want to take their case to the public.

- read the Bloomberg piece

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.